RLYB
Rallybio Corporation NASDAQ Listed Jul 29, 2021$15.97
+0.31%
vs $15.92
Mkt Cap $89.9M
52w Low $2.45
93.8% of range
52w High $16.87
50d MA $12.90
200d MA $7.63
P/E (TTM)
-10.0x
EV/EBITDA
—
P/B
1.6x
Debt/Equity
0.0x
ROE
-15.5%
P/FCF
-3.0x
RSI (14)
70.00
ATR (14)
$0.57
Beta
-1.20
50d MA
$12.90
200d MA
$7.63
Avg Volume
76.6K
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
234 Church Street · New Haven, CT 06510 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -1.24 | -1.28 | -3.2% | 9.60 | -0.2% | -1.0% | -0.9% | +2.6% | -3.0% | -2.9% | — |
| Nov 6, 2025 | AMC | -0.25 | -0.14 | +44.0% | 5.11 | -2.9% | -2.2% | +4.0% | +8.5% | -0.9% | -6.1% | — |
| Aug 7, 2025 | AMC | -0.20 | -0.22 | -12.8% | 4.09 | +1.2% | +3.9% | -6.4% | +1.3% | +6.2% | +2.1% | — |
| May 8, 2025 | AMC | -0.21 | -0.21 | +0.0% | 2.34 | +0.0% | +0.0% | +3.0% | -1.2% | +4.2% | +3.2% | — |
| Mar 13, 2025 | AMC | -0.27 | -0.25 | +7.4% | 5.25 | -2.1% | -3.6% | +1.6% | +14.4% | -0.9% | -3.9% | — |
| Nov 7, 2024 | AMC | -0.36 | -0.26 | +27.8% | 7.92 | +0.0% | +1.0% | +5.0% | +5.7% | -1.8% | -7.3% | — |
| Aug 8, 2024 | AMC | -0.42 | -0.37 | +11.9% | 9.52 | +3.4% | -4.2% | -3.5% | +3.6% | -4.4% | +1.8% | — |
| May 9, 2024 | AMC | -0.50 | -0.47 | +6.0% | 15.20 | +2.1% | -3.7% | -2.7% | +3.4% | +3.8% | -2.6% | — |
| Mar 12, 2024 | AMC | -0.44 | -0.50 | -13.6% | 13.44 | +1.8% | +4.8% | -9.1% | +1.2% | +0.6% | -1.8% | — |
| Nov 9, 2023 | AMC | -0.51 | -0.45 | +11.8% | 24.32 | -0.3% | -5.6% | -11.5% | -5.9% | -2.3% | -15.0% | — |
| Aug 8, 2023 | AMC | -0.48 | -0.46 | +4.2% | 42.24 | +0.0% | -0.4% | +6.5% | +3.6% | +3.4% | -0.2% | — |
| May 9, 2023 | AMC | -0.50 | -0.43 | +14.0% | 44.64 | +3.8% | -5.9% | -2.5% | +1.8% | +4.4% | +1.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 15 | Jones Trading | Downgrade | Buy → Hold | — | $2.16 | $2.10 | -2.8% | -2.8% | -4.3% | -0.5% | +6.0% | +7.1% |
| Apr 9 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $2.00 | $1.80 | -10.0% | +0.0% | +0.0% | +0.0% | +8.0% | -2.8% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.06 | $5.08 | +0.4% | +1.6% | +14.4% | -0.9% | -3.9% | -4.3% |
| Feb 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.97 | $5.84 | -2.2% | -2.8% | +8.3% | -4.0% | -2.5% | +4.6% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.52 | $7.52 | +0.0% | -1.9% | -3.5% | +1.1% | -1.1% | -1.7% |
| Dec 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.04 | $9.12 | +0.9% | -6.2% | +2.8% | -2.8% | +0.0% | +9.4% |
| Nov 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.91 | $8.00 | +1.1% | +3.2% | +2.9% | +2.9% | +1.9% | +6.4% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.92 | $7.92 | +0.0% | +1.0% | +5.0% | +5.7% | -1.8% | -7.3% |
| Oct 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.16 | $8.08 | -1.0% | +0.0% | +1.0% | -1.9% | +1.0% | +0.0% |
| Oct 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.36 | $9.36 | +0.0% | -4.3% | -2.7% | +0.9% | +0.9% | +1.8% |
| Sep 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.20 | $9.20 | +0.0% | -4.3% | +0.9% | +0.0% | -0.9% | +0.9% |
| Aug 26 | Evercore ISI | Maintains | Outperform → Outperform | — | $9.04 | $9.12 | +0.9% | +0.9% | +8.8% | -6.5% | +2.6% | -3.4% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.12 | $9.28 | +1.8% | -3.5% | +3.6% | -4.4% | +1.8% | -0.9% |
| May 15 | JP Morgan | Downgrade | Overweight → Neutral | — | $14.72 | $14.24 | -3.3% | +3.8% | -2.6% | -4.8% | -10.2% | +1.3% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.20 | $15.52 | +2.1% | -3.7% | -2.7% | +3.4% | +3.8% | -2.6% |
| Apr 19 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $13.36 | $13.20 | -1.2% | +5.4% | +0.6% | -1.7% | -9.2% | +4.4% |
| Apr 18 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $14.08 | $14.40 | +2.3% | -5.1% | +5.4% | +0.6% | -1.7% | -9.2% |
| Apr 11 | Wedbush | Maintains | Outperform → Outperform | — | $13.04 | $26.64 | +104.3% | +82.8% | -26.2% | -16.8% | -1.6% | -2.2% |
| Mar 13 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $13.44 | $13.68 | +1.8% | +4.8% | -9.1% | +1.2% | +0.6% | -1.8% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.44 | $13.68 | +1.8% | +4.8% | -9.1% | +1.2% | +0.6% | -1.8% |
| Feb 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.40 | $12.72 | +2.6% | +9.0% | +1.2% | +3.5% | -6.2% | +1.2% |
| Feb 7 | Wedbush | Maintains | Outperform → Outperform | — | $12.40 | $12.72 | +2.6% | +9.0% | +1.2% | +3.5% | -6.2% | +1.2% |
| Feb 7 | Jefferies | Downgrade | Buy → Hold | — | $12.40 | $12.72 | +2.6% | +9.0% | +1.2% | +3.5% | -6.2% | +1.2% |
| Feb 7 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $12.40 | $12.72 | +2.6% | +9.0% | +1.2% | +3.5% | -6.2% | +1.2% |
| Dec 21 | Evercore ISI | Maintains | Outperform → Outperform | — | $22.00 | $22.00 | +0.0% | -5.1% | +1.1% | -0.4% | -1.1% | -3.8% |
| Nov 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.56 | $16.80 | +1.4% | -5.3% | -2.6% | +16.8% | +18.4% | -3.8% |
| Nov 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.32 | $24.24 | -0.3% | -5.6% | -11.5% | -5.9% | -2.3% | -15.0% |
| Nov 10 | Wedbush | Maintains | Outperform → Outperform | — | $24.32 | $24.24 | -0.3% | -5.6% | -11.5% | -5.9% | -2.3% | -15.0% |
| Sep 5 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $43.28 | $43.60 | +0.7% | +0.4% | +0.0% | -2.4% | +0.4% | +0.6% |
| Sep 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $43.28 | $43.60 | +0.7% | +0.4% | +0.0% | -2.4% | +0.4% | +0.6% |
| Aug 10 | JP Morgan | Maintains | Overweight → Overweight | — | $42.08 | $42.08 | +0.0% | +6.5% | +3.6% | +3.4% | -0.2% | -9.3% |
| Jul 25 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $47.52 | $47.20 | -0.7% | -0.7% | +0.2% | +0.8% | -0.7% | +1.0% |
| Jun 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $44.72 | $45.52 | +1.8% | +1.3% | +4.2% | +0.0% | -0.3% | -11.1% |
| Jun 26 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $65.12 | $65.36 | +0.4% | -25.9% | +0.5% | -2.3% | -5.6% | +1.3% |
| Jun 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $65.12 | $65.36 | +0.4% | -25.9% | +0.5% | -2.3% | -5.6% | +1.3% |
| Apr 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.48 | $38.24 | +10.9% | +2.1% | -1.6% | +4.8% | -2.2% | +5.2% |
| Apr 10 | Wedbush | Maintains | Outperform → Outperform | — | $39.28 | $41.60 | +5.9% | +2.0% | -4.4% | -5.6% | -3.1% | -1.6% |
| Feb 22 | JMP Securities | Maintains | Market Outperform → Outperform | — | $56.88 | $58.16 | +2.3% | +5.2% | +2.9% | +0.3% | +1.2% | +0.8% |
| Dec 9 | JP Morgan | Maintains | Overweight → Overweight | — | $38.24 | $40.88 | +6.9% | +3.1% | -5.3% | +26.3% | +6.9% | +11.3% |
| Aug 9 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $84.80 | $83.12 | -2.0% | -2.9% | +4.3% | -0.6% | +10.4% | +9.9% |
| Mar 16 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $69.12 | $69.92 | +1.2% | -4.4% | +4.1% | -3.7% | -6.8% | -2.1% |
| Feb 22 | JMP Securities | Maintains | Market Outperform → Outperform | — | $103.28 | $107.60 | +4.2% | -9.1% | -4.3% | +0.4% | +2.7% | -5.1% |
| Aug 23 | TD Cowen | Maintains | Outperform → Outperform | — | $101.52 | $107.20 | +5.6% | +1.5% | +1.6% | -2.0% | +2.3% | -1.0% |
| Aug 23 | Jefferies | Maintains | Buy → Buy | — | $101.52 | $107.20 | +5.6% | +1.5% | +1.6% | -2.0% | +2.3% | -1.0% |
| Aug 23 | Evercore ISI | Maintains | Outperform → Outperform | — | $101.52 | $107.20 | +5.6% | +1.5% | +1.6% | -2.0% | +2.3% | -1.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 19, 2026 | ADAR1 Capital Management, LLC10% | — | Buy | 200 | $13.80 | $3K | 926,352 | +5.49% | -0.07% |
| May 19, 2026 | ADAR1 Capital Management, LLC10% | — | Buy | 10,000 | $13.98 | $140K | 926,152 | +5.49% | -0.07% |
| May 18, 2026 | ADAR1 Capital Management, LLC10% | — | Buy | 6,009 | $13.98 | $84K | 916,152 | +5.49% | -0.07% |
| May 12, 2026 | ADAR1 Capital Management, LLC10% | — | Buy | 800 | $13.83 | $11K | 830,584 | -0.98% | +2.75% |
| May 11, 2026 | ADAR1 Capital Management, LLC10% | — | Buy | 19,900 | $14.00 | $279K | 829,784 | -0.98% | +2.75% |
| May 11, 2026 | ADAR1 Capital Management, LLC10% | — | Buy | 25,000 | $14.00 | $350K | 809,884 | -0.98% | +2.75% |
| May 11, 2026 | ADAR1 Capital Management, LLC10% | — | Buy | 5,100 | $14.00 | $71K | 784,884 | -0.98% | +2.75% |
| May 5, 2026 | ADAR1 Capital Management, LLC10% | — | Buy | 35,101 | $14.00 | $491K | 779,784 | +0.69% | +2.28% |
| May 4, 2026 | ADAR1 Capital Management, LLC10% | — | Buy | 116,904 | $13.97 | $1.6M | 744,683 | +0.69% | +2.28% |
| May 4, 2026 | ADAR1 Capital Management, LLC10% | — | Buy | 3,900 | $13.90 | $54K | 627,779 | +0.69% | +2.28% |
8-K
Rallybio Corporation -- 8-K Filing
Jun 1
8-K · 1.02
!! High
Rallybio Corporation -- 8-K 1.02: Material Agreement Terminated
I cannot determine the specific reason for termination (breach, mutual, regulatory, or expiration) from the information provided, so I'm unable to write the requested sentence accurately without speculating.
May 4
S-4
!!! Very High
Rallybio Corporation -- Merger Registration
Rallybio Corporation shareholders will receive a name change to Candid Therapeutics, Inc. upon completion of a merger transaction.
Apr 24
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
An executive departure at Rallybio signals potential leadership instability and warrant expiration within 90 days post-merger, which could pressure stock price and dilute shareholder value.
Mar 31
S-4
!!! Very High
Unknown — Merger Registration
Rallybio is merging with an unknown entity, likely resulting in significant changes to ownership structure and stock terms that existing shareholders must evaluate for dilution and value implications.
Mar 17
8-K
Rallybio Corporation -- 8-K Filing
Rallybio's merger with Candid will convert Candid option holders' shares into Rallybio options, with final ownership percentages dependent on Rallybio's cash position at closing.
Mar 2
Institutional (13F) — Top 17
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 793,451 | $7M | New | Mar 2026 |
| 2 | Viking Global Investors | 524,347 | $5M | New | Mar 2026 |
| 3 | Renaissance Technologies Llc | 156,527 | $1M | New | Mar 2026 |
| 4 | Johnson & Johnson | 152,901 | $1M | New | Mar 2026 |
| 5 | Vanguard Capital Management Llc | 112,040 | $1M | New | Mar 2026 |
| 6 | Aju Ib Investment Co., Ltd. | 94,334 | $846K | New | Mar 2026 |
| 7 | Rangeley Capital, Llc | 30,130 | $270K | New | Mar 2026 |
| 8 | Adar1 Capital Management, Llc | 20,535 | $184K | New | Mar 2026 |
| 9 | Citadel Advisors Llc | 19,886 | $178K | New | Mar 2026 |
| 10 | Acadian Asset Management Llc | 10,433 | $92K | New | Mar 2026 |
| 11 | Ubs Group Ag | 7,914 | $71K | New | Mar 2026 |
| 12 | Jpmorgan Chase & Co | 2,497 | $20K | New | Mar 2026 |
| 13 | Hartford Financial Management Inc. | 812 | $7K | New | Mar 2026 |
| 14 | Bnp Paribas Financial Markets | 120 | $1K | New | Mar 2026 |
| 15 | Fortitude Family Office, Llc | 53 | $475 | New | Mar 2026 |
| 16 | Wells Fargo & Company/mn | 37 | $332 | New | Mar 2026 |
| 17 | Danske Bank A/s | 1 | $9 | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 4
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 15,111 | $114K | Feb 2026 |
| 2 | Fidelity Total Market Index Fund | 4,079 | $31K | Feb 2026 |
| 3 | Fidelity Series Total Market Index Fund | 3,763 | $28K | Feb 2026 |
| 4 | Fidelity Nasdaq Composite Index Fund | 3,003 | $23K | Feb 2026 |
Valuation
Market Cap
$89.9M
Enterprise Value
$35.2M
P/E (TTM)
-10.04x
Forward P/E
—
PEG Ratio
0.04x
P/B
1.55x
P/S
104.78x
P/FCF
-3.02x
EV/EBITDA
—
Shares Out
5.6M
Financials (TTM)
Revenue
$858K
Net Income
-$9.0M
EBITDA
-$28.0M
Free Cash Flow
-$29.8M
Op Cash Flow
-$29.8M
EPS Basic
$-1.59
EPS Diluted
$-1.59
EPS Forward
$-5.52
Gross Margin
89.3%
Op Margin
-3270.9%
Net Margin
-1046.4%
Balance Sheet
Total Assets
$62.3M
Total Liab.
$4.3M
Total Equity
$58.0M
Cash
$54.7M
LT Debt
$82K
Book Value/Sh
$10.30
Debt/Equity
0.00x
Current Ratio
14.50
Quick Ratio
14.50
Returns & Growth
ROE
-15.5%
ROA
-14.4%
ROIC
-48.3%
Rev Growth YoY
+34.9%
EPS Growth YoY
+85.1%
Price Returns
2W
+1.8%
1M
+61.0%
3M
+91.8%
6M
+177.5%
12M
+485.4%
Technicals
52W High
$16.87
52W Low
$2.45
50d MA
$12.90
200d MA
$7.63
RSI (14)
70.00
ATR (14)
$0.57
Beta
-1.20
Avg Volume
77K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 26, 2026 11:03pm
· Source: financialmodelingprep.com